Fig. 2: Flow Diagram for Clinical Trial Design with Indication of EEG Measurement Timepoints. | Translational Psychiatry

Fig. 2: Flow Diagram for Clinical Trial Design with Indication of EEG Measurement Timepoints.

From: ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers

Fig. 2

The phase 2a trial evaluating BPN14770 (Zatolmilast) utilized a cross-over design and enrolled 30 individuals with FXS. The 30 were then randomized into two groups and the first (baseline) EEG measurement was taken during screening. During period 1, half received BPN14770 and the other group received placebo. After period 1, another EEG was taken and was either the drug condition or placebo condition EEG measure depending on group. During period 2, the groups switched, and they received whichever intervention conditions they had not received in period 1. After period 2, the final EEG measurement was taken. Made with BioRender.

Back to article page